Interferon-gamma increases monocyte PD-L1 but does not diminish T-cell activation

Area of Science:

• Immunology
• Critical Care Medicine

Background:

• Sepsis and trauma can cause immune dysfunction, marked by decreased monocyte HLA-DR and altered cytokine responses, linked to mortality.
• Adaptive immune defects, including increased PD-L1 expression and T-cell anergy, are observed in these patients.

Purpose of the Study:

• To investigate the effects of interferon-gamma on monocyte PD-L1 expression and T-cell activation in an ex-vivo human whole blood model of infection.

Main Methods:

• Utilized an ex-vivo human whole blood model simulating infection.
• Stimulated monocytes with lipopolysaccharide (LPS) and interferon-gamma.
• Measured HLA-DR expression, cytokine production (TNF-α, IL-10), PD-L1 levels, and T-cell activation (CD4, CD8) via flow cytometry.

Main Results:

• Interferon-gamma increased monocyte HLA-DR expression and TNF-α production, while decreasing IL-10 levels in response to LPS.
• Both LPS and interferon-gamma elevated monocyte PD-L1 expression; their combination synergistically increased PD-L1.
• Despite increased PD-L1, interferon-gamma did not diminish CD4 and CD8 T-cell activation.

Conclusions:

• Interferon-gamma enhances monocyte inflammatory responses and PD-L1 expression without impairing T-cell activation.
• PD-L1 may not be a definitive marker for T-cell anergy in this context.
• Interferon-gamma shows potential as an immune adjuvant to improve monocyte function while maintaining T-cell responsiveness.